GANX
Gain Therapeutics, Inc.
There isn't enough reported data to score GANX yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
GANX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Unavailable | |
| Unavailable |
GANX's revenue and profitability are currently under pressure. There isn't enough data to rate its cash flow and balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
GANX PE Valuation
GANX has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
GANX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect GANX's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
GANX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.42 | +$0.16 |
| Q2 2026 | -$0.50 | +$0.10 |
| Q1 2026 | -$0.58 | +$0.25 |
| Q4 2025 | -$0.61 | +$0.28 |
| Q3 2025 | -$0.58 | +$0.52 |
| Q2 2025 | -$0.60 | +$0.70 |
| Q1 2025 | -$0.83 | +$0.67 |
| Q4 2024 | -$0.89 | +$0.82 |
GANX is still losing money, but far less than before: $0.42 per share over the past year, against $1.82 at its worst in mid-2023.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over GANX on earnings quality, reporting a profit while its opponent remains loss making.
GANX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2023 | $55.2K | +23% |
| Q2 2022 | $95.1K | +6.6% |
| Q1 2022 | $45K | +754% |
| Q4 2021 | $43.2K | +373% |
| Q3 2021 | $27.3K | +308% |
| Q2 2021 | $89.2K | +1299% |
| Q1 2021 | $5.3K | -21% |
GANX's revenue has slid since its 2022 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2023 | -9478% | -2171 points |
| Q2 2022 | -5443% | -1502 points |
| Q1 2022 | -7307% | +39513 points |
| Q4 2021 | -7426% | +10252 points |
| Q3 2021 | -16953% | -4721 points |
| Q2 2021 | -3941% | +4414 points |
| Q1 2021 | -46819% | -39143 points |
| Q4 2020 | -17678% | N/A |
GANX's operating margin was −9478% last quarter, up 7476 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
GANX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$4.7M | -$906K |
| Q4 2024 | -$3.5M | +$2.2M |
| Q3 2024 | -$6.1M | -$2.1M |
| Q4 2023 | -$5.7M | -$1.7M |
| Q3 2023 | -$4M | -$621.1K |
| Q2 2023 | -$5M | +$70.6K |
| Q1 2023 | -$4.2M | -$1.8M |
| Q4 2022 | -$3.9M | +$243.5K |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with GANX at down 19%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
GANX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +892K shares |
| 1 year | +44% | +13.4M shares |
| 3 years | +253% | +31.4M shares |
| 5 years | +269% | +31.9M shares |
| Available history | +332% | +33.6M shares |
GANX has 44M diluted shares, up 44% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over GANX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
GANX Net Leverage
GANX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
GANX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.2 | Neutral |
| Stochastic | 5.9 | Oversold |
GANX's weekly RSI is 33 (neutral) and its Stochastic is 6 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
GANX PE vs Healthcare Sector
GANX has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
GANX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.36 | 21% below |
| 20 week MA | $1.64 | 34% below |
| 50 week MA | $1.99 | 46% below |
| 100 week MA | $1.99 | 46% below |
| 200 week MA | $2.60 | 58% below |
GANX is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over GANX on trend strength, trading above more of its moving averages.
GANX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $12.2 | $5.70 | -53% |
| 2022 | $5.70 | $3.15 | -45% |
| 2023 | $3.15 | $3.27 | +3.8% |
| 2024 | $3.27 | $1.76 | -46% |
| 2025 | $1.76 | $3.15 | +79% |
| 2026 YTD | $3.15 | $1.08 | -66% |
GANX has finished lower in three of the last five years. It's down 66% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over GANX on returns for 2026, with the stronger performance.